# Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)

> **NCT00122317** · PHASE3 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 187 (actual)

## Conditions studied

- Paroxysmal Hemoglobinuria, Nocturnal

## Interventions

- **DRUG:** eculizumab

## Key facts

- **NCT ID:** NCT00122317
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2008-09
- **Final completion:** 2008-10
- **Target enrollment:** 187 (ACTUAL)
- **Last updated:** 2018-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00122317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00122317, "Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00122317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*